Novartis Vaccines appoints medical affairs director in Europe; Bristol-Myers submits HIV NDA; Opioid scripts surging for pregnant women;

@FiercePharma: Top-read FP news this weekend: PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. More | Follow @TracyStaton

@EricPFierce: Daiichi Sankyo lays out the roadmap for finalizing the Ranbaxy and Sun deal. News | Follow @EricPFierce

@CarlyHFierce: Editor's Corner: Vivus needs more than boardroom shuffling to keep up with Arena's Belviq. Article | Follow @CarlyHFierce

> Novartis Vaccines has appointed John Porter as its medical affairs director for northern Europe. Release

> The FDA has extended BioMarin's ($BMRN) market exclusivity for rare-disease drug Kuvan by 6 months. Release

> Bristol-Myers Squibb ($BMY) has submitted to the FDA an NDA for a fixed-dose combo tablet that treats HIV-1. Release

> The FDA has warned consumers that two herbal supplement weight-loss pills, Infinity and Lite Fit USA, contain a dangerous ingredient recalled from the market due to heart attack and stroke risks. More

> A new study shows the number of prescriptions for opioid painkillers for pregnant women is surging despite their unknown impact on developing fetuses. More (sub. req.)

Medical Device News

@FierceMedDev: Varian Medical pays $35M to settle Pitt patent spat. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: Deerfield bets on robotic surgery with OMNIlife science deal. Article | Follow @VarunSaxena2

@EmilyWFierce: Staples wants to make 3D printing mainstream with a new trial program in New York and L.A. More from MedCity News | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Abbott wins FDA nod for diabetes blood test. News

> Report: Covidien buys New Wave Surgical for $100M+. Article

> Edwards wins a battle in its ongoing TAVR patent war with Medtronic. Report

> Covidien snags FDA OK for a camera-equipped feeding tube. Item

Biotech News

@FierceBiotech: JNJ teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort. Story | Follow @FierceBiotech

@JohnCFierce: Cytos hits self-destruct button as PhIIb asthma study bombs. More | Follow @JohnCFierce

@DamianFierce: Two biotech/med tech IPOs expected this week in Vital Therapies and TriVascular Technologies. Item | Follow @DamianFierce

@EmilyMFierce: Essential immune organ regenerated in mice. More | Follow @EmilyMFierce

> Intercept grabs the spotlight at EASL, builds case for lead drug OCA. News

> Novartis slams the brakes on RNAi development efforts. Brief

> J&J axes a late-stage Botox rival, chopping project staffers. Story

CRO News

> Clinipace cozies up to Karyopharm to get its pipeline moving. Story

> Parexel amps up its imaging focus in rebranded informatics biz. More

> Bristol-Myers enlists DKSH to push its drugs in Asia. Article

> Pacira picks Patheon to hit the gas on pain drug production. News

> Catalent inks a biosimilar alliance with a Chinese drugmaker. Report

> CROs are spending more on merit raises, survey says. Item

Biotech IT News

> PatientsLikeMe inks 5-year deal with Genentech. More

> Big Pharma companies open up cancer trial comparator arm data. Story

> Cheminformatics skills shortage threatens Indian drug discovery program. News

> Cancer foundation aiming to build a database of 50,000 human genomes. Report

> Pharma continues to grapple with trial participants' use of social media. Article

> NCI plans database of patients who experience miraculous recoveries. Item

And Finally... Pfizer's ($PFE) consumer healthcare unit has teamed up with actor Josh Duhamel for its Advil Relief in Action campaign, which features a Mobile Relief Center tour making about 100 stops across the country. More

Suggested Articles

In a high-stakes patent lawsuit between the CAR-T companies of Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.